SMT202000222T1 - Adenovirus oncolitico che codifica per una proteina b7 - Google Patents
Adenovirus oncolitico che codifica per una proteina b7Info
- Publication number
- SMT202000222T1 SMT202000222T1 SM20200222T SMT202000222T SMT202000222T1 SM T202000222 T1 SMT202000222 T1 SM T202000222T1 SM 20200222 T SM20200222 T SM 20200222T SM T202000222 T SMT202000222 T SM T202000222T SM T202000222 T1 SMT202000222 T1 SM T202000222T1
- Authority
- SM
- San Marino
- Prior art keywords
- protein
- oncolytic adenovirus
- adenovirus encoding
- encoding
- oncolytic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507419.8A GB201507419D0 (en) | 2015-04-30 | 2015-04-30 | Virus |
| GBGB1516936.0A GB201516936D0 (en) | 2015-09-24 | 2015-09-24 | Virus |
| GBGB1522013.0A GB201522013D0 (en) | 2015-12-14 | 2015-12-14 | Virus |
| PCT/EP2016/059609 WO2016174200A1 (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
| EP16723043.2A EP3288573B1 (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000222T1 true SMT202000222T1 (it) | 2020-05-08 |
Family
ID=56008588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200222T SMT202000222T1 (it) | 2015-04-30 | 2016-04-29 | Adenovirus oncolitico che codifica per una proteina b7 |
Country Status (31)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112516179A (zh) | 2013-06-14 | 2021-03-19 | ę®čµå„„å čęÆę²»ēå ¬åø | ēØäŗbåč ŗē ęÆēē»čÆę¹ę”åå¶å |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| SG11201602887QA (en) | 2013-10-25 | 2016-05-30 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| SG11201708604TA (en) | 2015-04-30 | 2017-11-29 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
| JP6936221B2 (ja) | 2015-11-02 | 2021-09-15 | ćć”ć¤ć ćć©ć¤ć ć»ć©ćć„ć¼ćć£ćÆć¹ļ¼ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼£ļ½ļ¼ļ¼ē“°čå¤ćć”ć¤ć³ććŖćććććØćććę²»ēć§ć®ćććć®ä½æēØ |
| EA201891022A1 (ru) * | 2015-12-17 | 2019-01-31 | ŠŃŠ°Š¹Š¾ŠŗŃŃŃ Š¢ŠµŃŠ°ŠæŃŃŃŠøŠŗŃ ŠŠøŠ¼ŠøŃŠµŠ“ | ŠŠøŃŃŃ, ŠŗŠ¾Š“ŠøŃŃŃŃŠøŠ¹ Š°Š½ŃŠøŃŠµŠ»Š¾ Šŗ ŠŗŠ¾Š¼ŠæŠ»ŠµŠŗŃŃ tcr ŠøŠ»Šø ŃŃŠ°Š³Š¼ŠµŠ½Ń ŃŠŗŠ°Š·Š°Š½Š½Š¾Š³Š¾ Š°Š½ŃŠøŃŠµŠ»Š° |
| HUE072880T2 (hu) * | 2016-03-31 | 2025-12-28 | The European Molecular Biology Laboratory | AdenovĆrus szĆ”lfehĆ©rjĆ©kbƵl szĆ”rmazĆ³ mĆ³dosĆtott polipeptidek Ć©s a polipeptideket tartalmazĆ³ VLP-k |
| MY197324A (en) | 2016-08-29 | 2023-06-13 | Akamis Bio Ltd | Adenovirus armed with bispecific t cell activator |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CA3035615A1 (en) * | 2016-09-02 | 2018-03-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| AU2017335673B2 (en) | 2016-09-27 | 2024-11-14 | Sator Therapeutics LLC | Optimized oncolytic viruses and uses thereof |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| AU2018215558B2 (en) * | 2017-02-03 | 2023-05-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
| BR112019024656A2 (pt) * | 2017-05-25 | 2020-06-09 | Univ Central Florida Res Found Inc | vĆrus oncolĆticos para a sensibilizaĆ§Ć£o de cĆ©lulas tumorais para morte por cĆ©lulas exterminadoras naturais |
| KR102702230B1 (ko) * | 2017-05-26 | 2024-09-03 | ģķ¼ģ¼ķøģģģ¤, ģøģ½ķ¬ė ģ“ķ°ė | ķøėģ¤ģ§ģ ė³“ģ ķė ģ¬ģ”°ķ© ģė°ė øė°ģ“ė¬ģ¤ |
| JP7394628B2 (ja) * | 2017-06-01 | 2023-12-08 | ć¢ć«ćć¹ ćć¤ćŖ ćŖćććć | č «ēęŗ¶č§£ę§ć¦ć¤ć«ć¹ććć³ę¹ę³ |
| US11573230B2 (en) * | 2018-01-26 | 2023-02-07 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| US12404312B2 (en) | 2018-03-05 | 2025-09-02 | Massachusetts Eye And Ear Infirmary | Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| WO2019189643A1 (ja) * | 2018-03-30 | 2019-10-03 | å½ē«å¤§å¦ę³äŗŗę±äŗ¬å¤§å¦ | č «č¹ēŗēęå¶åč «ēęŗ¶č§£ę§ć¦ć¤ć«ć¹ |
| EP3856216A4 (en) * | 2018-09-10 | 2022-10-05 | Genesail Biotech (Shanghai) Co. Ltd. | MODIFIED ONCOLYTIC VIRUS, COMPOSITION AND USE THEREOF |
| TW202045544A (zh) | 2019-02-22 | 2020-12-16 | ē¾åęēę²»ēęéå ¬åø | ēØę¼ę²»ēļ¼°ļ¼¤ļ¼ļ¼¬ļ¼é°ę§č «ē¤ä¹ļ¼£ļ¼¤ļ¼ļ¼čå¤ēµę§åļ¼¦ļ½čåčē½ |
| AU2020232264B2 (en) * | 2019-03-05 | 2026-02-19 | Amgen Inc. | Use of oncolytic viruses for the treatment of cancer |
| EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | MƩtodos e composiƧƵes para prevenir diabetes do tipo 1 |
| EP3970754A4 (en) * | 2019-05-14 | 2023-08-02 | Oncolys BioPharma, Inc. | METHOD OF ADMINISTRATION OF ONCOLYTIC VIRUS TO TUMOR TISSUE AND DEVICE FOR ADMINISTRATION |
| GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| GB202102049D0 (en) * | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| EP4332218A4 (en) * | 2021-06-03 | 2024-09-18 | Shanghai Yunying Biopharmaceutical Technology Co., Ltd. | ONCOLYTIC VIRUS VECTOR AND USE THEREOF |
| AU2022349649A1 (en) | 2021-09-23 | 2024-04-04 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
| EP4499846A1 (en) * | 2022-03-25 | 2025-02-05 | UniversitƤt ZĆ¼rich | Adenoviral mediated targeting of activated immune cells |
| WO2024243578A1 (en) | 2023-05-25 | 2024-11-28 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thƩrapie gƩnique. |
| CN1115414C (zh) | 1993-07-13 | 2003-07-23 | ē½ēŗ³-åøęå ē½č±å°č”份ęéå ¬åø | ēØäŗåŗå ę²»ēēē ęÆč½½ä½ |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | ęå°¼å ęÆčÆē©å ¬åø | ēØäŗčæē¤ę²»ēåé¢é²ēč“ē»čē åē ęÆ |
| EP1036183B1 (en) | 1997-02-20 | 2007-10-03 | The Johns Hopkins University School Of Medicine | Mutations in atp-dependent transposition proteins that reduce target-site specificity |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | ęå·čµē®ēē©ęęÆå¼åęéå ¬åø | åŗå å·„ēØč ŗē ęÆåå ¶ēØé |
| US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
| JP4409097B2 (ja) | 1998-12-09 | 2010-02-03 | ć¢ć”ćŖć«åč”å½ | č¤ę°ć®å ±åŗęæååćēŗē¾ććēµęćććÆćæć¼ććć³ćć®å©ēØ |
| ES2372823T3 (es) | 1999-05-17 | 2012-01-26 | Crucell Holland B.V. | Adenovirus recombinante del serotipo ad11. |
| AU5464000A (en) | 1999-06-01 | 2000-12-18 | University Of Washington | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| ATE312189T1 (de) * | 2000-01-21 | 2005-12-15 | Biovex Ltd | VirusstƤmme fĆ¼r die onkolytische behandlung von krebs |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| AU2001265154A1 (en) | 2000-05-31 | 2001-12-11 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| US7459153B2 (en) | 2001-01-04 | 2008-12-02 | Wadell Goeran | Viral vectors for gene therapy |
| US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| EP1470233A1 (en) * | 2002-02-01 | 2004-10-27 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| AU2003223775A1 (en) | 2002-04-30 | 2003-11-17 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| CN1705740B (zh) * | 2002-10-15 | 2013-07-24 | 佩å°Ā·ę¾å Ā·éå°å§ | å ·ęåååŗå č”Øč¾¾ēč ŗē ęÆåå ¶åŗēØ |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
| US20050136035A1 (en) | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| CA2527369A1 (en) | 2003-07-18 | 2005-02-03 | Onyx Pharmaceuticals, Inc. | Subgroup b adenoviral vectors for treating disease |
| US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
| WO2005118825A2 (en) | 2004-05-26 | 2005-12-15 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | ęé½åŗ·å¼ēē©ē§ęęéå ¬åø | čæē¤ē»čäøäøč”Øč¾¾å ē«č°čå ågm-csfēęŗ¶ē¤ę§č ŗē ęÆéē»ä½ēęå»ŗåå ¶åŗēØ |
| US20060292682A1 (en) * | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| CN101068933A (zh) * | 2004-08-25 | 2007-11-07 | ē»čåŗå ē³»ē»ęéå ¬åø | ēØäŗčæē¤ē»čå¢å¼ŗč½¬åƼēēŗ¤ē»“äæ®é„°ēč ŗē ęÆč½½ä½ |
| JP2008511336A (ja) * | 2004-09-01 | 2008-04-17 | ć¢ć”ćŖć«åč”å½ | å ē«åę§ćå¢å ććć¢ććć¦ć¤ć«ć¹ććÆćæć¼ćć¤ć³ććć§ēØććę¹ę³ |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| AU2006284756B2 (en) | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | UniversitƤt Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| EP2094284A2 (en) | 2006-12-22 | 2009-09-02 | Bayer Schering Pharma AG | Generation of oncolytic adenoviruses and uses thereof |
| TW200951143A (en) | 2008-05-27 | 2009-12-16 | Oncolytics Biotech Inc | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | ęµę±ēå·„å¤§å¦ | ęęåÆåØåé¶åę§č°ę§ęŗ¶ē¤č ŗē ęÆpCN305č½½ä½åå ¶ęå»ŗę¹ę³äøåŗēØ |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | FundaciĆ³ Privada Institut D'investigaciĆ³ BiomĆØdica De Bellvitge | Adenovirus oncolĆticos para el tratamiento del cĆ”ncer. |
| EP2486137B1 (en) * | 2009-10-05 | 2018-05-30 | Ya-Fang Mei | Replication-competent ad11p based viral vectors |
| CN103237889B (zh) | 2010-08-16 | 2017-04-05 | čØå ēē©ē ē©¶å¦é¢ | č ŗē ęÆē»č£ ę¹ę³ |
| BR112013006699A2 (pt) | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolĆtico que codifica anticorpos anti-ctl4-4 monoclonais, cĆ©lula e composiĆ§Ć£o farmacĆŖutica compreendendo o mesmo, mĆ©todo de produĆ§Ć£o de anticorpo monoclonal humano especĆfico para ctla-4 em uma cĆ©lula e uso do referido vetor adenoviral |
| EP2619224A1 (en) * | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| WO2013074507A2 (en) | 2011-11-14 | 2013-05-23 | Regenerative Sciences, Llc | Suspended particle delivery systems and methods |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | éč„æåøčå¤§å¦ | äøę„ę³ęå»ŗęŗåø¦å¤ęŗåŗå ēd24ēŗ¤ē»“čē½äæ®é„°ēę”件å¤å¶åč ŗē ęÆč½½ä½åå ¶åŗēØ |
| CN105407902A (zh) | 2013-03-05 | 2016-03-16 | č“åå»å¦é¢ | ęŗ¶ē¤ē ęÆ |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| SG11201602887QA (en) | 2013-10-25 | 2016-05-30 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
| KR20160137946A (ko) | 2013-11-22 | 2016-12-02 | ėģģģ“ķøė¦ģ¤, ģøģ½ķ¬ė ģ“ķ°ė | ė©“ģ ģøķ¬ ģź·¹ģ± ģģ©ģ²“ ģģ©ģ (ė¤)ė„¼ ė°ķķė ģė°ė øė°ģ“ė¬ģ¤ |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| GB201510197D0 (en) * | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| AU2016232009B2 (en) | 2015-03-17 | 2021-07-15 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| SG11201708604TA (en) | 2015-04-30 | 2017-11-29 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | ŠŃŠ°Š¹Š¾ŠŗŃŃŃ Š¢ŠµŃŠ°ŠæŃŃŃŠøŠŗŃ ŠŠøŠ¼ŠøŃŠµŠ“ | ŠŠøŃŃŃ, ŠŗŠ¾Š“ŠøŃŃŃŃŠøŠ¹ Š°Š½ŃŠøŃŠµŠ»Š¾ Šŗ ŠŗŠ¾Š¼ŠæŠ»ŠµŠŗŃŃ tcr ŠøŠ»Šø ŃŃŠ°Š³Š¼ŠµŠ½Ń ŃŠŗŠ°Š·Š°Š½Š½Š¾Š³Š¾ Š°Š½ŃŠøŃŠµŠ»Š° |
| SG11201808058PA (en) | 2016-03-18 | 2018-10-30 | Nantcell Inc | Multimodal vector for dendritic cell infection |
| MY197324A (en) | 2016-08-29 | 2023-06-13 | Akamis Bio Ltd | Adenovirus armed with bispecific t cell activator |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| JP7394628B2 (ja) * | 2017-06-01 | 2023-12-08 | ć¢ć«ćć¹ ćć¤ćŖ ćŖćććć | č «ēęŗ¶č§£ę§ć¦ć¤ć«ć¹ććć³ę¹ę³ |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-04-29 SG SG11201708604TA patent/SG11201708604TA/en unknown
- 2016-04-29 SM SM20200222T patent/SMT202000222T1/it unknown
- 2016-04-29 DK DK16723043.2T patent/DK3288573T3/da active
- 2016-04-29 CN CN201680024692.0A patent/CN107690479B/zh active Active
- 2016-04-29 US US15/570,100 patent/US11000559B2/en active Active
- 2016-04-29 WO PCT/EP2016/059609 patent/WO2016174200A1/en not_active Ceased
- 2016-04-29 KR KR1020247006825A patent/KR102854512B1/ko active Active
- 2016-04-29 BR BR122018004815A patent/BR122018004815A2/pt not_active Application Discontinuation
- 2016-04-29 KR KR1020177032425A patent/KR102643574B1/ko active Active
- 2016-04-29 KR KR1020187030538A patent/KR20180118249A/ko not_active Withdrawn
- 2016-04-29 PE PE2018000519A patent/PE20181140A1/es unknown
- 2016-04-29 SI SI201630679T patent/SI3288573T1/sl unknown
- 2016-04-29 RS RS20200325A patent/RS60105B1/sr unknown
- 2016-04-29 MY MYPI2017703967A patent/MY183703A/en unknown
- 2016-04-29 AU AU2016256582A patent/AU2016256582B2/en active Active
- 2016-04-29 LT LTEP16723043.2T patent/LT3288573T/lt unknown
- 2016-04-29 BR BR112017023171-9A patent/BR112017023171A2/pt active Search and Examination
- 2016-04-29 HU HUE16723043A patent/HUE048320T2/hu unknown
- 2016-04-29 SG SG10201901482XA patent/SG10201901482XA/en unknown
- 2016-04-29 CA CA2984038A patent/CA2984038C/en active Active
- 2016-04-29 JP JP2017552966A patent/JP6931229B2/ja active Active
- 2016-04-29 ES ES16723043T patent/ES2780366T3/es active Active
- 2016-04-29 PT PT167230432T patent/PT3288573T/pt unknown
- 2016-04-29 MX MX2017013684A patent/MX2017013684A/es unknown
- 2016-04-29 PE PE2017002327A patent/PE20180241A1/es unknown
- 2016-04-29 KR KR1020257028976A patent/KR20250134212A/ko active Pending
- 2016-04-29 IL IL284375A patent/IL284375B/en unknown
- 2016-04-29 HR HRP20200439TT patent/HRP20200439T1/hr unknown
- 2016-04-29 SG SG10201803081TA patent/SG10201803081TA/en unknown
- 2016-04-29 EA EA201791971A patent/EA037611B1/ru unknown
- 2016-04-29 EP EP16723043.2A patent/EP3288573B1/en active Active
- 2016-04-29 PL PL16723043T patent/PL3288573T3/pl unknown
- 2016-04-29 EP EP18159326.0A patent/EP3391892A1/en active Pending
- 2016-04-29 CN CN201810213204.1A patent/CN108396015B/zh active Active
- 2016-08-08 US US15/231,422 patent/US10124028B2/en active Active
-
2017
- 2017-05-03 US US15/586,091 patent/US10548929B2/en active Active
- 2017-10-25 CO CONC2017/0010831A patent/CO2017010831A2/es unknown
- 2017-10-25 PH PH12017501942A patent/PH12017501942A1/en unknown
- 2017-10-26 IL IL255286A patent/IL255286B/en active IP Right Grant
- 2017-10-26 CL CL2017002731A patent/CL2017002731A1/es unknown
- 2017-10-30 SA SA520412637A patent/SA520412637B1/ar unknown
- 2017-10-30 SA SA517390260A patent/SA517390260B1/ar unknown
- 2017-10-31 US US15/799,644 patent/US10322152B2/en active Active
-
2018
- 2018-02-28 AU AU2018201446A patent/AU2018201446B2/en active Active
- 2018-03-05 CL CL2018000587A patent/CL2018000587A1/es unknown
- 2018-03-07 ZA ZA201801589A patent/ZA201801589B/en unknown
- 2018-03-08 JP JP2018041788A patent/JP6928380B2/ja active Active
- 2018-03-12 IL IL258044A patent/IL258044B/en unknown
- 2018-09-18 US US16/134,704 patent/US10849945B2/en active Active
-
2020
- 2020-03-18 CY CY20201100253T patent/CY1122833T1/el unknown
- 2020-08-25 AU AU2020223665A patent/AU2020223665A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/301,502 patent/US20210338753A1/en not_active Abandoned
- 2021-08-05 JP JP2021129196A patent/JP7162929B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258044A (en) | Oncolytic adenovirus encoding the b7 protein | |
| IL260027A (en) | A group b adenovirus that encodes an anti-tcr-complex antibody or particle | |
| ZA201802261B (en) | Polypeptides | |
| PL3659614T3 (pl) | Onkolityczny wirus krowianki | |
| IL254577A0 (en) | polypeptides | |
| GB201713765D0 (en) | Modified adenovirus | |
| GB201409634D0 (en) | Intra block copy mode encoding choice | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| SG11201706882VA (en) | Polypeptides | |
| ZA201704366B (en) | Il-17a-binding polypeptides | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORĪ³) | |
| GB201417535D0 (en) | Adapting encoding properties | |
| IL267267A (en) | Vibration sensing system with wavelength encoding | |
| GB201405891D0 (en) | Modified antimicrobial peptides | |
| EP3239962A4 (en) | Encoding device | |
| GB2539417B (en) | Optimized multi-view image encoding | |
| GB201520655D0 (en) | Multi-mode sensor | |
| GB201614607D0 (en) | Modified adenovirus | |
| GB201706219D0 (en) | Modified adenovirus | |
| GB201700663D0 (en) | Modified adenovirus | |
| GB201401159D0 (en) | Adenovirus | |
| GB201516655D0 (en) | IX sensor | |
| GB201502178D0 (en) | Detecting polypeptides |